Cancer Cell
Volume 22, Issue 3, 11 September 2012, Pages 359-372
Journal home page for Cancer Cell

Article
Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma

https://doi.org/10.1016/j.ccr.2012.07.014Get rights and content
Under an Elsevier user license
open archive

Summary

Diffuse large B cell lymphoma (DLBCL) is a clinically and biologically heterogeneous disease with a high proliferation rate. By integrating copy number data with transcriptional profiles and performing pathway analysis in primary DLBCLs, we identified a comprehensive set of copy number alterations (CNAs) that decreased p53 activity and perturbed cell cycle regulation. Primary tumors either had multiple complementary alterations of p53 and cell cycle components or largely lacked these lesions. DLBCLs with p53 and cell cycle pathway CNAs had decreased abundance of p53 target transcripts and increased expression of E2F target genes and the Ki67 proliferation marker. CNAs of the CDKN2A-TP53-RB-E2F axis provide a structural basis for increased proliferation in DLBCL, predict outcome with current therapy, and suggest targeted treatment approaches.

Highlights

► A complementary set of CNAs decrease p53 activity and deregulate cell cycle ► DLBCLs either have multiple CNAs of p53/cell cycle components or lack these lesions ► The p53/cell cycle CNAs predict outcome and suggest targeted treatment approaches ► DLBCLs with p53/cell cycle CNAs have increased genomic instability

Cited by (0)

8

These authors contributed equally to this work

9

Present address: Section of Computational Biomedicine, Boston University School of Medicine, Boston, MA 02118, USA

10

Present address: Sanofi-Aventis K. K., 163-1488 Tokyo, Japan

11

Present address: Novartis, Cambridge, MA 02139, USA

12

Present address: Infinity Pharmaceuticals, Cambridge, MA 02139, USA